A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy

Deirdre O'Mahony, John C. Morris, Cate Quinn, Wendy Gao, Wyndham H. Wilson, Barry Gause, Stefania Pittaluga, Sattva Neelapu, Margaret Brown, Thomas A. Fleisher, James L. Gulley, Jeffrey Schlom, Robert Nussenblatt, Paul Albert, Thomas A. Davis, Israel Lowy, Mike Petrus, Thomas A. Waldmann, John Edward Janik

Research output: Contribution to journalArticle

137 Citations (Scopus)

Abstract

Purpose: Eleven patients with progressive advanced malignancy after administration of a cancer vaccine received a fully human anti-CTLA-4 monoclonal antibody (ipilimumab). The primary end point was to determine drug toxicity. Tumor response, tumor-specific CD8+ T-cell immune responses, and modulation of CD4+ CD25+ FoxP3+ regulatory T-cell (Treg) numbers were secondary end points. Experimental Design: Three patients with colon cancer, four with non - Hodgkin's lymphoma, and four with prostate cancer were treated. The first dose was given at 3 mg/kg and subsequent doses were administered monthly at 1.5 mg/kg for a total of four cycles. Results: Tumor regression was observed in two patients with lymphoma; one of which obtained a partial response of 14-month duration. Ipilimumab was well tolerated with predominantly grade 1/2 toxicities. One drug-related grade 3 toxicity was observed. One patient died within 30 days of treatment due to progressive colon cancer. No increase in vaccine-specific T-cell responses was observed after therapy. Tregs as detected by expression of CD4 +CD25+CD62L+ declined at early time points but rebounded to levels at or above baseline values at the time of the next infusion. Conclusions: Ipilimumab treatment depressed Treg numbers at early time points in the treatment cycle but was not accompanied by an increase in vaccine-specific CD8+ T-cell responses in these patients previously treated with a variety of investigational anticancer vaccines. A partial response was observed in one patient with follicular lymphoma. A phase I/II trial evaluating ipilimumab in patients with follicular lymphoma is currently ongoing.

Original languageEnglish (US)
Pages (from-to)958-964
Number of pages7
JournalClinical Cancer Research
Volume13
Issue number3
DOIs
StatePublished - Feb 1 2007

Fingerprint

Cancer Vaccines
Neoplasms
Follicular Lymphoma
Vaccines
T-Lymphocytes
Colonic Neoplasms
Regulatory T-Lymphocytes
Therapeutics
Drug-Related Side Effects and Adverse Reactions
Non-Hodgkin's Lymphoma
Lymphoma
Prostatic Neoplasms
Research Design
Cell Count
Monoclonal Antibodies
ipilimumab
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

O'Mahony, D., Morris, J. C., Quinn, C., Gao, W., Wilson, W. H., Gause, B., ... Janik, J. E. (2007). A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clinical Cancer Research, 13(3), 958-964. https://doi.org/10.1158/1078-0432.CCR-06-1974

A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. / O'Mahony, Deirdre; Morris, John C.; Quinn, Cate; Gao, Wendy; Wilson, Wyndham H.; Gause, Barry; Pittaluga, Stefania; Neelapu, Sattva; Brown, Margaret; Fleisher, Thomas A.; Gulley, James L.; Schlom, Jeffrey; Nussenblatt, Robert; Albert, Paul; Davis, Thomas A.; Lowy, Israel; Petrus, Mike; Waldmann, Thomas A.; Janik, John Edward.

In: Clinical Cancer Research, Vol. 13, No. 3, 01.02.2007, p. 958-964.

Research output: Contribution to journalArticle

O'Mahony, D, Morris, JC, Quinn, C, Gao, W, Wilson, WH, Gause, B, Pittaluga, S, Neelapu, S, Brown, M, Fleisher, TA, Gulley, JL, Schlom, J, Nussenblatt, R, Albert, P, Davis, TA, Lowy, I, Petrus, M, Waldmann, TA & Janik, JE 2007, 'A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy', Clinical Cancer Research, vol. 13, no. 3, pp. 958-964. https://doi.org/10.1158/1078-0432.CCR-06-1974
O'Mahony, Deirdre ; Morris, John C. ; Quinn, Cate ; Gao, Wendy ; Wilson, Wyndham H. ; Gause, Barry ; Pittaluga, Stefania ; Neelapu, Sattva ; Brown, Margaret ; Fleisher, Thomas A. ; Gulley, James L. ; Schlom, Jeffrey ; Nussenblatt, Robert ; Albert, Paul ; Davis, Thomas A. ; Lowy, Israel ; Petrus, Mike ; Waldmann, Thomas A. ; Janik, John Edward. / A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. In: Clinical Cancer Research. 2007 ; Vol. 13, No. 3. pp. 958-964.
@article{409578e4745b47328d3a1fafc88d803d,
title = "A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy",
abstract = "Purpose: Eleven patients with progressive advanced malignancy after administration of a cancer vaccine received a fully human anti-CTLA-4 monoclonal antibody (ipilimumab). The primary end point was to determine drug toxicity. Tumor response, tumor-specific CD8+ T-cell immune responses, and modulation of CD4+ CD25+ FoxP3+ regulatory T-cell (Treg) numbers were secondary end points. Experimental Design: Three patients with colon cancer, four with non - Hodgkin's lymphoma, and four with prostate cancer were treated. The first dose was given at 3 mg/kg and subsequent doses were administered monthly at 1.5 mg/kg for a total of four cycles. Results: Tumor regression was observed in two patients with lymphoma; one of which obtained a partial response of 14-month duration. Ipilimumab was well tolerated with predominantly grade 1/2 toxicities. One drug-related grade 3 toxicity was observed. One patient died within 30 days of treatment due to progressive colon cancer. No increase in vaccine-specific T-cell responses was observed after therapy. Tregs as detected by expression of CD4 +CD25+CD62L+ declined at early time points but rebounded to levels at or above baseline values at the time of the next infusion. Conclusions: Ipilimumab treatment depressed Treg numbers at early time points in the treatment cycle but was not accompanied by an increase in vaccine-specific CD8+ T-cell responses in these patients previously treated with a variety of investigational anticancer vaccines. A partial response was observed in one patient with follicular lymphoma. A phase I/II trial evaluating ipilimumab in patients with follicular lymphoma is currently ongoing.",
author = "Deirdre O'Mahony and Morris, {John C.} and Cate Quinn and Wendy Gao and Wilson, {Wyndham H.} and Barry Gause and Stefania Pittaluga and Sattva Neelapu and Margaret Brown and Fleisher, {Thomas A.} and Gulley, {James L.} and Jeffrey Schlom and Robert Nussenblatt and Paul Albert and Davis, {Thomas A.} and Israel Lowy and Mike Petrus and Waldmann, {Thomas A.} and Janik, {John Edward}",
year = "2007",
month = "2",
day = "1",
doi = "10.1158/1078-0432.CCR-06-1974",
language = "English (US)",
volume = "13",
pages = "958--964",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy

AU - O'Mahony, Deirdre

AU - Morris, John C.

AU - Quinn, Cate

AU - Gao, Wendy

AU - Wilson, Wyndham H.

AU - Gause, Barry

AU - Pittaluga, Stefania

AU - Neelapu, Sattva

AU - Brown, Margaret

AU - Fleisher, Thomas A.

AU - Gulley, James L.

AU - Schlom, Jeffrey

AU - Nussenblatt, Robert

AU - Albert, Paul

AU - Davis, Thomas A.

AU - Lowy, Israel

AU - Petrus, Mike

AU - Waldmann, Thomas A.

AU - Janik, John Edward

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Purpose: Eleven patients with progressive advanced malignancy after administration of a cancer vaccine received a fully human anti-CTLA-4 monoclonal antibody (ipilimumab). The primary end point was to determine drug toxicity. Tumor response, tumor-specific CD8+ T-cell immune responses, and modulation of CD4+ CD25+ FoxP3+ regulatory T-cell (Treg) numbers were secondary end points. Experimental Design: Three patients with colon cancer, four with non - Hodgkin's lymphoma, and four with prostate cancer were treated. The first dose was given at 3 mg/kg and subsequent doses were administered monthly at 1.5 mg/kg for a total of four cycles. Results: Tumor regression was observed in two patients with lymphoma; one of which obtained a partial response of 14-month duration. Ipilimumab was well tolerated with predominantly grade 1/2 toxicities. One drug-related grade 3 toxicity was observed. One patient died within 30 days of treatment due to progressive colon cancer. No increase in vaccine-specific T-cell responses was observed after therapy. Tregs as detected by expression of CD4 +CD25+CD62L+ declined at early time points but rebounded to levels at or above baseline values at the time of the next infusion. Conclusions: Ipilimumab treatment depressed Treg numbers at early time points in the treatment cycle but was not accompanied by an increase in vaccine-specific CD8+ T-cell responses in these patients previously treated with a variety of investigational anticancer vaccines. A partial response was observed in one patient with follicular lymphoma. A phase I/II trial evaluating ipilimumab in patients with follicular lymphoma is currently ongoing.

AB - Purpose: Eleven patients with progressive advanced malignancy after administration of a cancer vaccine received a fully human anti-CTLA-4 monoclonal antibody (ipilimumab). The primary end point was to determine drug toxicity. Tumor response, tumor-specific CD8+ T-cell immune responses, and modulation of CD4+ CD25+ FoxP3+ regulatory T-cell (Treg) numbers were secondary end points. Experimental Design: Three patients with colon cancer, four with non - Hodgkin's lymphoma, and four with prostate cancer were treated. The first dose was given at 3 mg/kg and subsequent doses were administered monthly at 1.5 mg/kg for a total of four cycles. Results: Tumor regression was observed in two patients with lymphoma; one of which obtained a partial response of 14-month duration. Ipilimumab was well tolerated with predominantly grade 1/2 toxicities. One drug-related grade 3 toxicity was observed. One patient died within 30 days of treatment due to progressive colon cancer. No increase in vaccine-specific T-cell responses was observed after therapy. Tregs as detected by expression of CD4 +CD25+CD62L+ declined at early time points but rebounded to levels at or above baseline values at the time of the next infusion. Conclusions: Ipilimumab treatment depressed Treg numbers at early time points in the treatment cycle but was not accompanied by an increase in vaccine-specific CD8+ T-cell responses in these patients previously treated with a variety of investigational anticancer vaccines. A partial response was observed in one patient with follicular lymphoma. A phase I/II trial evaluating ipilimumab in patients with follicular lymphoma is currently ongoing.

UR - http://www.scopus.com/inward/record.url?scp=33847407907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847407907&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-06-1974

DO - 10.1158/1078-0432.CCR-06-1974

M3 - Article

C2 - 17289891

AN - SCOPUS:33847407907

VL - 13

SP - 958

EP - 964

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 3

ER -